Abstract | BACKGROUND: METHODS: RESULTS: Changes in serum phosphate at the end of treatment were -0.82 mmol/L in the JTT-751 group and -0.78 mmol/L in the sevelamer group, establishing non-inferiority of JTT-751 compared with sevelamer (least squares mean, -0.03 mmol/L; 95% confidence interval, -0.13 to 0.07 mmol/L). Corrected serum calcium increased and PTH decreased from baseline within both groups; changes between groups were similar. Gastrointestinal disorders were the most common adverse events in both groups; the incidence of diarrhea was higher in the JTT-751 group, while constipation occurred frequently in the sevelamer group. Treatment with JTT-751 resulted in significant relative increases in serum ferritin and transferrin saturation. CONCLUSIONS: TRIAL REGISTRATION NUMBER: CTI-111433 (The Japan Pharmaceutical Information Center at: http//www.clinicaltrials.jp). Date of registration: 7 March 2011.
|
Authors | Keitaro Yokoyama, Takashi Akiba, Masafumi Fukagawa, Masaaki Nakayama, Kenichi Sawada, Yuji Kumagai, Glenn M Chertow, Hideki Hirakata |
Journal | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
(Nephrol Dial Transplant)
Vol. 29
Issue 5
Pg. 1053-60
(May 2014)
ISSN: 1460-2385 [Electronic] England |
PMID | 24376274
(Publication Type: Clinical Trial, Phase III, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Chelating Agents
- Ferric Compounds
- Parathyroid Hormone
- Polyamines
- ferric citrate
- Sevelamer
|
Topics |
- Adult
- Chelating Agents
(therapeutic use)
- Female
- Ferric Compounds
(therapeutic use)
- Humans
- Hyperphosphatemia
(diagnosis, drug therapy, etiology)
- Japan
- Kidney Failure, Chronic
(complications, therapy)
- Male
- Middle Aged
- Parathyroid Hormone
(blood)
- Polyamines
(therapeutic use)
- Renal Dialysis
- Sevelamer
- Young Adult
|